PMID- 35265100
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 12
DP  - 2021
TI  - HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional 
      Prognostic Value for Gallbladder Carcinoma.
PG  - 831318
LID - 10.3389/fgene.2021.831318 [doi]
LID - 831318
AB  - Gallbladder carcinoma (GBC) is responsible for 80%-95% of biliary tract 
      malignancies and has a dismal prognosis. Human epidermal growth factor receptor 2 
      (HER2) is a promising therapeutic target of GBC. Through immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH) methods, HER2 expression and 
      gene amplification were identified on high-output tissue microarrays (TMAs) 
      developed in 306 GBC cases to investigate its relationship with GBC and 
      clinicopathological characteristics. Adenocarcinomas accounted for 223 (72.9%) of 
      the cases, with 62 (27.8%) being papillary adenocarcinoma or having partial 
      papillary structure. HER2 positivity was studied in 16.1% (36/223) of patients 
      with adenocarcinoma and 41.9% (26/62) in adenocarcinoma with papillary 
      structures. For 143 radically resected primary GBC cases with 24 HER2-positive 
      tumors, survival data were valid; the median survival time was not reached, and 
      the 5-year survival rate was 52.9%. All patients in stages 0-I survived, and the 
      results of the HER2-positive group and the stage II HER2-negative group were 
      similar (p = 0.354). However, in stage III, the mortality rate in the 
      HER2-positive group was reduced (p = 0.005) and that in stage IV was higher (p = 
      0.005). In conclusion, HER2 positivity was significantly higher in patients with 
      papillary GBC. The predictive value of HER2 varies by clinical stage, with no 
      prediction in the early stages, better in stage III, and worse in stage IV.
CI  - Copyright (c) 2022 Chen, Xu, Shen, Luo, Jiang, Wang, Li and Hou.
FAU - Chen, Lingli
AU  - Chen L
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Xu, Lei
AU  - Xu L
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Shen, Licheng
AU  - Shen L
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Luo, Rongkui
AU  - Luo R
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Jiang, Dongxian
AU  - Jiang D
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Wang, Yueqi
AU  - Wang Y
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Hou, Yingyong
AU  - Hou Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220204
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC8899850
OTO - NOTNLM
OT  - HER2
OT  - HER2 positivity
OT  - gallbladder carcinomas
OT  - papillary adenocarcinoma
OT  - prognosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/11 06:00
MHDA- 2022/03/11 06:01
PMCR- 2022/02/04
CRDT- 2022/03/10 05:44
PHST- 2021/12/08 00:00 [received]
PHST- 2021/12/27 00:00 [accepted]
PHST- 2022/03/10 05:44 [entrez]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/03/11 06:01 [medline]
PHST- 2022/02/04 00:00 [pmc-release]
AID - 831318 [pii]
AID - 10.3389/fgene.2021.831318 [doi]
PST - epublish
SO  - Front Genet. 2022 Feb 4;12:831318. doi: 10.3389/fgene.2021.831318. eCollection 
      2021.